GlassScriptPhysician profile
Heike I Schmolck
NPI 1972646917
$2,478.45
in general payments reported to CMS, 2019-2025
34 companies · $258 in 2025
The $258 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,268 · 2020: $125 · 2021: $162 · 2022: $37.62 · 2023: $454 · 2024: $174 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $886.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $540.52 | 2019-2024 | Qulipta, Ubrelvy |
| Biogen, INC. | $434.71 | 2019-2025 | Vumerity, Aduhelm, Tysabri |
| Novartis Pharmaceuticals Corporation | $171.54 | 2019 | |
| Supernus Pharmaceuticals, INC. | $138.56 | 2019-2020 | |
| Amgen INC. | $100.19 | 2019-2020 | |
| Lilly USA, LLC | $96.95 | 2019-2025 | Kisunla, Amyvid |
| Ucb, INC. | $95.14 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $92.56 | 2019-2025 | Austedo Xr |
| Emd Serono, INC. | $79.17 | 2019 | |
| Acorda Therapeutics, INC | $70.29 | 2019 | |
| Pfizer INC. | $67.21 | 2019-2025 | |
| Argenx US, INC. | $52.79 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Sunovion Pharmaceuticals INC. | $51.46 | 2019 | |
| Ge Healthcare | $48.88 | 2019 | |
| Eisai INC. | $41.17 | 2019 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $37.59 | 2024 | |
| Merz North America, INC. | $36.36 | 2019 | |
| Tanabe Pharma America, INC. | $32.70 | 2019 | |
| Csl Behring | $31.77 | 2025 | Hizentra |
| Upsher-Smith Laboratories LLC | $30.04 | 2019 | |
| Mdd US Operations, LLC | $28.47 | 2019 | |
| Genentech USA, INC. | $21.90 | 2024 | Ocrevus Zunovo, Ocrevus |
| Amneal Pharmaceuticals LLC | $18.03 | 2025 | Crexont |
| Vertical Pharmaceuticals, LLC | $17.95 | 2019 | |
| Alnylam Pharmaceuticals INC. | $17.90 | 2019 | |
| Kyowa Kirin, INC. | $15.96 | 2020 | |
| Medtronic USA, INC. | $15.62 | 2019 | |
| Jazz Pharmaceuticals INC. | $14.50 | 2019 | |
| Tg Therapeutics, INC. | $14.11 | 2025 | |
| Celgene Corporation | $14.08 | 2025 | Zeposia |
| Adamas Pharmaceuticals, INC. | $13.39 | 2019 | |
| Allergan, INC. | $12.94 | 2019 | |
| Promius Pharma LLC | $12.34 | 2019 | |
| Genzyme Corporation | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heike Schmolck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.